Navigation Links
Micromet Expands Committed Equity Financing Facility to $75 Million
Date:12/2/2008

BETHESDA, Md., Dec. 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has entered into an agreement expanding its Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited, a private investment group. Under the terms of the agreement, Kingsbridge has committed to provide up to $75 million of capital during the next three years through the purchase of newly-issued shares of Micromet's common stock. Micromet has no obligation to access the facility and will have full control over the amount and the timing of any financing under the facility, subject to certain conditions outlined below. This agreement replaces the Company's 2006 CEFF agreement under which Kingsbridge had committed up to $25 million of capital. The Company did not raise capital under the 2006 CEFF.

"We believe that the closing of our recent $40 million PIPE financing puts us in a strong financial position. The expanded CEFF provides Micromet with additional financial strength and flexibility, which has never been more important than in the current financial environment," stated Dr. Christian Itin, President and CEO of Micromet.

Key provisions of the CEFF are as follows:

-- After the Securities and Exchange Commission (SEC) declares effective the registration statement to be filed by Micromet covering the resale of the shares of common stock issuable in connection with the new CEFF, Micromet can access up to $75 million from Kingsbridge through December 1, 2011, in exchange for newly-issued shares of Micromet's common stock, subject to the terms of the CEFF. The maximum amount of the new CEFF will be reduced by any amounts drawn down on the August 2006 CE
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Today, iHealth Lab Inc. announced it has ... for its first institutional round of funding. The strategic ... reach, accelerate growth and innovation, and invest in additional ... Xiaomi Ventures will join iHealth,s board of directors, bringing ... ecommerce. "We are very pleased to have ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Equipment Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), ... End Users (Hospitals), Advanced technologies - Global Forecast ... Market is poised to reach $19,786.3 Million by ... CAGR of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 The ... that Drive Medical Design and Manufacturing has joined the ... its CEO Harvey Diamond have been actively ... year history, as it has quickly grown into a ... corporate partners like Drive allows AAHomecare to increase efforts ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Young Innovations, Inc. (Nasdaq: YDNT ) today announced that it will broadcast ... call on Wednesday, July 21, 2010 at 11:00 a.m. Central ... InterCall at http://tinyurl.com/yiq210 . Access to the live audio broadcast will also ... , , ...
... Ill. , July 14 RoundTable Healthcare ... the health-care industry, announced today that it has entered ... portfolio companies, Bioniche Pharma Holdings Limited ("Bioniche Pharma") to ... pharmaceutical company, for $550 million in cash. ...
Cached Medicine Technology:Young Innovations, Inc. Provides 2nd Quarter Conference Call Details 2RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc. 2RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc. 3
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... course from Winter & Alvin has just been ... excitement throughout the personal development community. The media ... attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative ... topic of great interest for many entrepreneurs and ...
(Date:9/22/2014)... 22, 2014 QueenBeeTickets.com has the largest ... larger with discount Stevie Wonder tickets. The phenomenal singer/songwriter ... Tour,” and 11 cities have been put on the ... , Click Here to view the selection ... , Stevie Wonder ticket sales are bound to be ...
(Date:9/22/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Twix . , Mars Chocolate North America announced ... Stand Up Pouch with specific code date are recalled due ... is that Twix Unwrapped Bites 7 oz. Stand Up Pouch ... writing them on the ingredient label. , In case ...
(Date:9/22/2014)... 2014 The Center for Health ... ERC as one of the NorthCoast 99 ... places to work for top talent. This award recognizes ... maintain great workplaces that support the attraction, retention and ... staffing and workforce, development and training, compensation and rewards, ...
(Date:9/22/2014)... The Ruby Report was launched by the ... Conference in Louisville, Kentucky. This release followed the May ... reception attended by 60 people from the local area. ... gained while conducting her research, what drove her to ... and what she believes companies can do to be ...
Breaking Medicine News(10 mins):Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2Health News:Discount Stevie Wonder Tickets: QueenBeeTickets.com Delights Customers with Discounted Concert Tickets for Stevie Wonder’s 11-City Tour Set to Kick off in November 2Health News:Mars Chocolate North America Recalls Twix Bites: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 3Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2
... 10 Caliper Life Sciences, Inc. (Nasdaq: ... at the Cowen and Company 29th Annual Health ... on Tuesday, March 17 at 10:15 a.m. ET. ... will be providing an update on the company,s ...
... Report Finds Public Health Programs At Risk During Economic ... and the Robert Wood Johnson Foundation (RWJF) today released ... received less funding from the federal government than Northeastern ... for disease prevention programs, which can amount to millions ...
... Designed to Optimize Treatment of Patients with Coronary ... Abbott ( NYSE: ABT ) today announced ... a next-generation balloon dilatation catheter with high-pressure capability ... coronary artery disease (CAD) during angioplasty procedures. VOYAGER ...
... 10 Johnson & Johnson will participate in the ... Monday, March 16th at the Boston Marriott Copley Place ... President, Finance and Chief Financial Officer, will represent the ... Time). The webcast will be available to investors and ...
... 10 The Kavli Foundation has announced the appointment ... - only the second president since the Foundation was ... Foundation,s President in late April of this year.Dr. Conn ... acclaimed scientist whose research is focused on plasma physics ...
... in the March issue of the Journal of ... transplantation should be used with caution in patients older ... with high rates of mortality after one year in ... the gold-standard treatment for a variety of end-stage lung ...
Cached Medicine News:Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 2Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 3Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 2Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 3Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 5Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 2Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 3Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 4Health News:Journal of American College of Surgeons finds lung transplantation should be used in older patients 2
... enzyme immunoassay kit for the quantitative ... in serum. Enzyme immunoassay (EIA) permits ... protein hormones in body fluids and ... and specific assay. This enzyme immunoassay ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
Medicine Products: